Jaume Capdevila, MD, PhD, discusses phase 1 data showing promising efficacy and manageable safety for obrixtamig in patients with high DLL3-expressing extrapulmonary neuroendocrine carcinomas, along with ongoing trials evaluating its use in both monotherapy and combination settings.
As summer heats up, pharmacists can provide travel vaccines and other recommendations.
In March, Utah became the first state to completely ban fluoridation.
Data from a phase 1b study showed significantly reduced toxicity compared with conventional oral dosing.
Scott Soefje, PharmD, MBA, BCOP, shares insights about the evolving role of pharmacists at the 2025 OPC meeting.
Failure to quickly notify patients could result in significant harm.
New research reveals that bedtime antihypertensive dosing does not improve cardiovascular outcomes in frail older adults, emphasizing safety over timing.
Suzetrigine, a new nonopioid pain reliever, gains FDA approval for treating moderate to severe acute pain in adults, offering a safer alternative to opioids.
New research reveals that combining bimagrumab and semaglutide enhances fat loss while preserving muscle mass, revolutionizing obesity treatment strategies.
![[AI Generated] 3D Medical Cross-Section of Diabetic Vascular Disease - Microvascular Damage Mechanism](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/a1eb8eb82c084cc01b983b073be9e81ef74df663-1200x673.jpg?w=350&fit=crop&auto=format)
HMGCR inhibitors were found to significantly increase the risk of experiencing microvascular complications in patients with diabetes, whereas NPC1L1 inhibitors were found to reduce the risk.
Gabe Hinojosa, PharmD, BCOP, shares key data for pharmacists from the 2025 American Society of Clinical Oncology Annual Meeting.
Compared with prior intravenous formulations, the autoinjector is a more accessible administration method for children and their caregivers.
Six years following vaccination with 23-valent pneumococcal polysaccharide vaccine in a Chinese population, antibody levels remained high, although not as high as 28 days following vaccination.
Hulio shows comparable efficacy and safety to Humira in treating chronic plaque psoriasis, supporting its FDA interchangeability status.
Low-energy total diet replacement programs show promise for individuals with obesity and type 2 diabetes, without increasing eating disorder risks.
Manish Agrawal, MD, explores the evolving role of pharmacists in psychedelic-assisted therapy, highlighting ongoing efforts to develop standardized protocols and the emerging involvement of pharmacy teams in patient education and safety.
The session highlighted tirzepatide’s unique mechanism of action, based on comprehensive clinical data and real-world evidence.
Hospitals and health systems proactively monitor and manage data accuracy with third-party administrators to maintain 340B program compliance and maximize benefits for vulnerable patient populations.
Datopotamab deruxtecan gains FDA approval, offering new hope for adults with advanced EGFR-mutated non-small cell lung cancer after prior therapies.
Continuous glucose monitoring (CGM) is poised to transform type 2 diabetes management.
Glucocorticoids alone were found to reduce treatment failure and fever duration, but the combination with intravenous immunoglobulin (IVIG) significantly reduced the need for adjunctive immunotherapy following treatment.
Ready-to-use glucagon simplifies hypoglycemia rescue by providing easy-to-use options for patients and caregivers.
These changes are creating operational challenges for oncology infusion centers.
Manish Agrawal, MD, discusses the expanding influence of his group-based psychedelic therapy model in oncology and beyond, highlighting its adaptation in military posttraumatic stress disorder (PTSD) research, the sustained benefits of long-term patient integration, and growing institutional interest in psychedelic-assisted therapy.
Pharmacists have the skills to improve patient outcomes and relieve burdens on other providers.
Lorundrostat reduces blood pressure and urine albumin-to-creatinine ratio in patients with chronic kidney disease (CKD) and hypertension.
Continuous glucose monitors provide individuals with type 2 diabetes with real-time, actionable insights about their health.
Oral semaglutide shows promising cardiovascular benefits for type 2 diabetes patients, reducing major adverse events by 14% in the SOUL trial.
CagriSema shows promising weight loss and metabolic benefits in recent trials, offering new hope for obesity and type 2 diabetes management.
Experts discuss the low prescription rates of ready-to-use glucagon for individuals with diabetes.
